

## PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg  
 Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_  
 Patient Preferred Location: \_\_\_\_\_

## DIAGNOSIS & CLINICAL INFORMATION

<ICD 10 CODE REQUIRED>

**ICD 10 Code (PROVIDE COMPLETE CODE)**

M1A.\_\_\_\_\_ 0 Chronic Gout, w/o Tophi  
 M1A.\_\_\_\_\_ 1 Chronic Gout, w/ Tophi  
 Other: \_\_\_\_\_

**Prescribing Information**

It is recommended that the patient discontinue oral urate-lowering medications 2-3 days (up to one week) before starting Krystexxa.

Recent data suggests that patients may have improved outcomes when immunomodulators are taken with Krystexxa.

- **The recommended dosage is Krystexxa 8 mg every two weeks, co-administered w/weekly methotrexate 15 mg orally.**
- **Krystexxa alone may be used in patients for whom methotrexate is contraindicated or not clinically appropriate.**

**REQUIRED:** Demographics and Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.  
**LAB RESULTS:** : G6PD, baseline uric acid > 6.0 mg/dL.

## PRESCRIPTION

**Pre-Medications**

*Required:*  
 Acetaminophen: 650 mg PO, may repeat q 4-6 hours, PRN infusion reaction  
 Diphenhydramine: 25 mg IVP, may repeat q 6 hours, PRN infusion reaction  
 Methylprednisolone: 125 mg SIVP  
 Other: \_\_\_\_\_

**Lab Orders+**

*Required:* Uric Acid Level, 24-72 hours prior to infusion  
 If Uric Acid Level > 6 mg/dL upon two consecutive lab draws, hold dose, and contact prescriber

**+Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider**

**KRYSTEXXA (pegloticase)**

**Loading Dose**

IV: Infuse 8 mg in 250 mL of 0.9% Sodium Chloride over 2 hours, every 2 weeks for one year

**Is the patient on any other disease modifying therapy?    Yes    No**  
**If yes, please note therapy and last dose:** \_\_\_\_\_

**Post Treatment Observations:** The patient is observed for 60 minutes following each infusion.

**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

## PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_  
 Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_  
 Supervising Physician: \_\_\_\_\_ (If Applicable)  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_